Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Trial details
- Registry ID
- NCT06982521
- Drugs studied
- Capivasertib, Fulvestrant, Zovegalisib
TrialRedline tracks 3 clinical trials sponsored by Relay Therapeutics, Inc.: 1 Phase 3, 1 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 | Capivasertib, Fulvestrant, Zovegalisib | Recruiting | 2028-04-30Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)NCT06789913 | RLY-2608 | Recruiting | 2031-07Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid TumorsNCT07584226 | RLY-8161 | Recruiting | 2029-05-31Estimated |
Names as written in the registry records.